These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9350053)

  • 1. Characterization of ligand binding, DNA binding and phosphorylation of progesterone receptor by two novel progesterone receptor antagonist ligands.
    Hurd C; Underwood B; Herman M; Iwasaki K; Kloosterboer HJ; Dinda S; Moudgil VK
    Mol Cell Biochem; 1997 Oct; 175(1-2):205-12. PubMed ID: 9350053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.
    Hurd C; Nag K; Khattree N; Alban P; Dinda S; Moudgil VK
    Mol Cell Biochem; 1999 Sep; 199(1-2):49-56. PubMed ID: 10544951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation.
    Gass EK; Leonhardt SA; Nordeen SK; Edwards DP
    Endocrinology; 1998 Apr; 139(4):1905-19. PubMed ID: 9528977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antiprogestins Org 31806 and 31710: interaction with mammalian progesterone receptor and DNA binding of antisteroid receptor complexes.
    Mizutani T; Bhakta A; Kloosterboer HJ; Moudgil VK
    J Steroid Biochem Mol Biol; 1992 Aug; 42(7):695-704. PubMed ID: 1504008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone receptor and the mechanism of action of progesterone antagonists.
    Edwards DP; Altmann M; DeMarzo A; Zhang Y; Weigel NL; Beck CA
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):449-58. PubMed ID: 7626494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay.
    Leonhardt SA; Altmann M; Edwards DP
    Mol Endocrinol; 1998 Dec; 12(12):1914-30. PubMed ID: 9849965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor.
    Beck CA; Zhang Y; Weigel NL; Edwards DP
    J Biol Chem; 1996 Jan; 271(2):1209-17. PubMed ID: 8557652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells.
    Klein-Hitpass L; Cato AC; Henderson D; Ryffel GU
    Nucleic Acids Res; 1991 Mar; 19(6):1227-34. PubMed ID: 2030942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor.
    DeMarzo AM; Oñate SA; Nordeen SK; Edwards DP
    Biochemistry; 1992 Nov; 31(43):10491-501. PubMed ID: 1420166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity.
    Wei LL; Hawkins P; Baker C; Norris B; Sheridan PL; Quinn PG
    Mol Endocrinol; 1996 Nov; 10(11):1379-87. PubMed ID: 8923464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of retinoblastoma protein by hormonal and antihormonal agents in T47D breast cancer cells.
    Alban P; Hurd C; Dinda S; Khattree N; Moudgil VK
    J Steroid Biochem Mol Biol; 2001 May; 77(2-3):135-41. PubMed ID: 11377979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antiprogestins RU486 and ZK98299 affect follicle-stimulating hormone secretion differentially on estrus, but not on proestrus.
    Ringstrom SJ; Szabo M; Kilen SM; Saberi S; Knox KL; Schwartz NB
    Endocrinology; 1997 Jun; 138(6):2286-90. PubMed ID: 9165013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-specific dynamics of the progesterone receptor in living cells and during chromatin remodeling in vitro.
    Rayasam GV; Elbi C; Walker DA; Wolford R; Fletcher TM; Edwards DP; Hager GL
    Mol Cell Biol; 2005 Mar; 25(6):2406-18. PubMed ID: 15743833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antiprogestins on the rate of proliferation of breast cancer cells.
    Iwasaki K; Underwood B; Herman M; Dinda S; Kodali S; Kloosterboer HJ; Hurd C; Moudgil VK
    Mol Cell Biochem; 1999 Aug; 198(1-2):141-9. PubMed ID: 10497889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.
    Wardell SE; Narayanan R; Weigel NL; Edwards DP
    Mol Endocrinol; 2010 Feb; 24(2):335-45. PubMed ID: 20008003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
    Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
    Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZK98299, a novel antiprogesterone that does not interact with chicken oviduct progesterone receptor.
    Moudgil VK; Nath R; Bhakta A; Nakao M
    Biochim Biophys Acta; 1991 Sep; 1094(2):185-92. PubMed ID: 1892900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299.
    Takimoto GS; Tasset DM; Eppert AC; Horwitz KB
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3050-4. PubMed ID: 1557412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins.
    Wagner BL; Pollio G; Giangrande P; Webster JC; Breslin M; Mais DE; Cook CE; Vedeckis WV; Cidlowski JA; McDonnell DP
    Endocrinology; 1999 Mar; 140(3):1449-58. PubMed ID: 10067874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization.
    Bocquel MT; Ji J; Ylikomi T; Benhamou B; Vergezac A; Chambon P; Gronemeyer H
    J Steroid Biochem Mol Biol; 1993 Apr; 45(4):205-15. PubMed ID: 8499329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.